Taken together, treatment with TF3 could enhance the sensitivity of ovarian cancer A2780/CP70 and OVCAR3 cells to cisplatin by upregulating CTR1 protein expression in the cells. This evidence concerns the gene SLC31A1 and ovarian carcinoma.